

Curriculum vitae della Dott.ssa Carmen Criscitiello

EDUCATION

October 2005: M.D. Degree, Medical School, University of Naples “Federico II”, Italy

January 2010: Residency in Oncology, University of Naples “Federico II”, Italy

January 2013: PhD in Medical Oncology and Surgery and Clinical Immunology, Division of Medical Oncology, Seconda Università degli Studi di Napoli (SUN), Italy

PROFESSIONAL EXPERIENCE

November 2020 – present: Assistant Professor, University of Milan, Italy

January 2018- present: Scientist & Senior Staff Member appointed with High Specialty in Immunotherapy at the Division of Experimental Therapeutics, European Institute of Oncology – Milano, Italy

July 2016: Visiting Physician at the Breast Cancer Department, Dana Farber Cancer Institute, Boston U.S.A.

January 2015-present: Scientist & Senior Staff Member, Division of Experimental Therapeutics, European Institute of Oncology – Milano, Italy

June 2014: Visiting Researcher at the M.D. Anderson Cancer Center, Houston U.S.A.

October 2011-December 2014: Fellowship in Medical Oncology, Division of Medical Oncology, European Institute of Oncology – Milano, Italy

April 2009- September 2011: TransBIG Fellowship, Translational Research Unit, Institut Jules Bordet - Brussels, Belgium

2003-2005: Internship, Division of Medical Oncology, Medical School, University of Naples “Federico II”, Italy

HONORS AND AWARDS

2020 - to date ESMO Leadership Generation Task Force Deputy Chair

2018 - to date: AIOM Breast Cancer Guidelines Panel Member

2018- to date: Member of the ESMO Press & Media Affairs Committee

January 2018: "Back from San Antonio" Award for the best publication

2017-to date: National Scientific Qualification as Associate Professor of Oncology

2017-to date: ESMO faculty member for the Breast cancer faculty group

2016: ESMO Leaders Generation Programme

2014: Member of the Scientific Committee for Metastatic Breast Cancer at the 2014 ESMO annual meeting – Madrid, Spain

EDITORIAL BOARDS

January 2021 – to date: Associate Editor for Frontiers in Oncology - Board of Breast Cancer

October 2019 – to date: Associate Editor for Frontiers in Oncology - Board of Women's Cancer

2019: Associate Editor for the ESMO 2019 Congress Newspaper

2018: Associate Editor for the ESMO 2018 Congress Newspaper
January 2018- to date: ESMO Open - Cancer Horizons

REVIEWER ACTIVITY

Lancet Oncology, Annals of Oncology, European Journal of Cancer, Journal of Translational Medicine, The Breast, The Oncologist, NPJ

MEMBERSHIPS AND AFFILIATIONS

2008- to date: Member of the European Society of Medical Oncology (ESMO)

2013-to date: Member of the Associazione Italiana di Oncologia Medica (AIOM)

2016-to date: Member of the Breast Cancer Working Group for *Alleanza Contro il Cancro* (ACC)

PERSONAL SKILLS AND COMPETENCES:

Mother Tongue: Italian

Other Languages: English and French

LIST OF PRESENTATIONS AT SCIENTIFIC MEETINGS:

- December 17, 2022 Bologna: “the pathway of cure for patients with breast cancer “. Invited talk:” the advent of PARP inhibitors”
- December 15, 2022 Roma: “Breast Oncology News & Discussion “. Invited talk:” the definition of high-risk in TNBC”
- November 29-30, 2022 Rome BREAST LIFE 2.0 Journey of patients with mBC. Invited talk:” Evidence supporting the role of talazoparib”
- November 23, 2022 Napoli, REALNESS - inTRODucing the new possible in mTNBC. HR+ disease at diagnosis
- November 18, 2022 Palermo Progetto Amazzone Invited talk:”the cure of breast cancer in 2022” The cure of breast cancer in 2022
- November 12-13, 2022 Milan Preceptorship Breast Cancer Invited talk: “Adjuvant endocrine therapy and CDK 4-6 inhibitors”
- November 10, 2022 Milan Course on analysis and methodology of clinical trials. Tutor at the interactive workshop on clinical trials in oncology
- October 28-29, 2022 Naples Italian Breast Group Annual Meeting. Invited talk:” Updates on early stage Luminal breast cancer”
- October 21-22, 2022 Novara INNOVATORS IN BREAST CANCER. Invited talk:” systemic therapy for HER2+ metastatic breast cancer”
- October 12, 2022 webinar New opportunities and challenges in HER2+ metastatic breast cancer. Invited speaker: Barriers and opportunities to optimize the pathway of patients with brain metastases
- October 8, 2022 CAMPUS BREAST MEETING 2022, Rome. Invited speaker:” Basics of signaling pathways in breast cancer development and progression”

- October 3, 2022 AIOM annual congress, Rome. Life 2 women. How Monaleesa powered a new Italian renaissance. Invited speaker
- October 3, 2022 AIOM annual congress, Rome. Educational session – Treatment of metastatic breast cancer: is the cure possible? Luminal-like breast carcinoma. Invited speaker.
- October 1, 2022 ESMO Preceptorship on breast cancer. Invited talk on “endocrine agents and biologic agents in HR+/HER2- metastatic breast cancer”. Lugano. Switzerland
- September 30, 2022 webinar “Multidisciplinary management of breast cancer”. Invited talk on “news in HR+/HER2- metastatic breast cancer
- September 23-24, 2022 scientific chair “Life2Women”, Milan
- September 20, 2022 invited speaker at “Olympic games in Oncology”, Rome
- September 15, 2022 ESMO Relive, invited talk “news on TNBC”, webinar
- September 15, 2022 webinar “PD-L1 assessment through CPS in TNBC: let’s get started”. Invited talk: “The clinical significance of the test”
- July 6-7, 2022 “EvoLVER – Abemaciclib, progettato per essere diVERso. La storia continua”. Invited talk:” LET’S EVOLVER Abemaciclib, innovation why?”
- June 29-30, 2022 “Research Generators - Widening options in HER2+ metastatic breast cancer”. Invited talk:” State of the art and future challenges in HER2+ breast cancer with brain metastases”
- June 14, 2022 Officially licensed Best of ASCO 2022 annual meeting. Invited talk:” The agnostic pathway to approval”
- May 27, 2022 webinar “PIK3CA in breast cancer: strategies to perform the best test to the single patient”. Invited talk:” Therapeutic opportunities in metastatic breast cancer with PIK3CA mutations”
- May 20, 2022 Naples “2022 Cancer Research: from New Orleans to Naples “invited speaker. “New horizons in neoadjuvant immunotherapy”
- May 18, 2022 Rome "BRING IN...THE EXPERTS". Invited speaker “Bring in... the experts in metastatic breast cancer!”
- May 3-5, 2022 ESMO Breast Cancer Congress 2022 (3-5 May), Berlin, Germany - invited Discussant in the Mini Oral session 3
- April 29-30, 2022 Roma "Dive into New Horizons" – Diving into overall survival benefit
- April 26, 2022 O.P.E.R.A. BREAST - “Oncology ProfEssional Remote Academy “- Webinar on breast cancer. Invited talk: “Treatment of metastatic triple negative breast cancer: the role of immunotherapy”
- April 21, 2022 FAD webinar “breast cancer”. Invited talk: “Therapeutic options in HER2+ breast cancer”
- April 21, 2022 Milan “La gestione pratica della paziente con carcinoma mammario HR+/HER2-: un percorso condiviso” - Tavola rotonda multidisciplinare: tumor burden e processo decisionale
- April 6, 2022: FAD webinar “Le nuove prospettive per il carcinoma mammario triplo-negativo e HER2-positivo: il ruolo centrale della Breast Unit”
- April 1, 2022 Naples: Breast Journal Club – l’importanza della ricerca in oncologia: La direzione della ricerca, uno sguardo al futuro

- March 8, 2022 webinar “Women4women”. Invited talk: “real world data with CDK 4/6 inhibitors”
- March 3, 2022 webinar “The management of adverse events in the treatment of TNBC”
- January 15, 2022 Back from San Antonio, Genova Italy. Invited talk “biological news in HER2+ disease”
- December 18, 2021 5th meeting on targeted therapies and immunotherapy in oncology. Invited talk “CDK 4/6 inhibitors in breast cancer”
- December 17, 2021 MBN2021 oncoplastic breast meeting. Invited talk “Management of primary systemic endocrine treatment. Trials-time to surgery-endocrine treatment after partial or no response”
- December 14, 2021 "WEBEXPERT - HIGHLIGHTS SABCS 2021". Invited talk “neoadjuvant/adjuvant HR+/HER2- breast cancer”
- December 9, 2021 invited speaker at Oligometastasis and stereotactic body radiotherapy in the era of systemic targeted therapies and immunotherapy held in Milan, Italy. Invited talk “Combination of radiotherapy and new drugs in oligometastatic breast cancer: the medical oncologist’s point of view”
- November 25, 2021 webinar “What’s new in HER2+ breast cancer”, moderator.
- November 19, 2021 invited speaker at Young oncologists in Immunoncology held virtually. Invited talk “New perspectives: from subtypes to new immune pathways”
- November 12-13, 2021, invited speaker at Breast cancer: evidence and new hopes expert meeting held at Verduno (CN) Italy. Invited talk: “emerging therapies for metastatic breast cancer: looking at the future”
- November 2021 Advanced Breast Cancer Sixth International Consensus Conference (ABC6)– Virtual conference Satellite symposium Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. Real world discussion
- October 2021, webinar Diagnostic of PIK3CA mutational status in breast cancer. Invited talk:” new therapeutic opportunities in advanced ER+/HER2- breast cancer with PIK3CA mutations
- September 25-26, 2021, invited speaker at Breastics24h held online
- September 24, 2021 Invited speaker at Oncology Race “current algorithm in HR+/HER2- metastatic breast cancer
- September 23, 2021 ESMO Relive, invited talk “immunotherapy news”
- September 10-11, 2021 Innovators in Breast Cancer Novara Italy. Invited talk “Questions for the pathologist by a clinician “
- June 29, 2021 Breast talk. De novo metastatic disease case presentation
- June 29, 2021 Breast Cancer Retreat 2021. Invited talk: “Overview of CDK 4/6 inhibitors in Luminal MBC”
- June 25, 2021 Pfizer Symposium at “Medisprof’s Best of ASCO 2021 Conference” (Romanian Best of ASCO). Invited talk:” From Clinical Trials to Real-World Effectiveness: Charting a new standard in HR+/HER2- ABC”

- June 23, 2021 BConnect – Virtual Connected Education VCoE; Verzenios case presentation
- June 22, 2021 evoluzione del trattamento della paziente con carcinoma mammario metastatico HR+/HER2-. Dall'Mbc all'adiuvante.
- June 15, 2021 YBO: Unmet need in breast cancer care. Invited talk: “Selecting the best immunotherapy regimen in breast cancer”
- May 27, 2021 virtual lecture for Maltese oncologists: “overall survival data and latest updates in CDK 4/6 inhibitors”
- May 26, 2021 AIOM webinar “Therapeutic strategy in HR+/HER2- mBC”. Invited talk: How to select patients
- May 21, 2021 Women’s Outline: from clinical outcomes to patients profiles. How to select CDK4/6 inhibitor treatment
- May 10, 2021 CGP ROADSHOW 2021 breast cancer
- May 8, 2021 ESMO Breast Cancer Virtual Congress 2021. Invited Discussant in the Proffered Paper session 2
- May 5, 2021 AIOM webinar “Immunotherapy in breast cancer”. Invited talk: Immunotherapy in breast cancer: clinical trials’ results
- April 19, 2021 ESO e-session Early breast cancer: Adjuvant versus neoadjuvant chemotherapy
- March 31, 2021 webinar “Webreast: conversation on abemaciclib”.
- March 26, 2021 webinar “Together is better: update on HR+/HER2- breast cancer”. Invited talk: Evolution in the treatment of metastatic HR+/HER2- breast cancer
- March 25, 2021 moderator web conference “HR+/HER2- breast cancer: new paradigms”
- March 23, 2021 Real world data in metastatic breast cancer between daily practice, research and regulatory. Invited talk: Real world data in HER2+ metastatic breast cancer
- March 10, 2021 webinar: the role of communication in breast cancer
- March 8, 2021 webinar women for women: The use of CDK 4/6 inhibitors in breast cancer patients with co-morbidities
- March 1, 2021 Webinar PIK3CA mutation and breast cancer. Talk: biologic rational for the use of PI3K inhibitors
- January 16, 2021 Back From San Antonio: “New biologic findings in HER2+ breast cancer”
- December 10, 2020. The Latvian association of oncologists and breast diseases. Lecture: Recent developments in the diagnostic and treatment of breast cancer
- November 18, 2020. YO-IO: Young Oncologists in immunoncology. Talk: State-of-art: immunotherapy in breast cancer. From neoadjuvant to first line.
- November 16, 2020. Special breast 2020, annual meeting on HR+/HER2- metastatic breast cancer. Talk: Pathology framework, therapeutic strategies and positioning of choices
- November 2020, FAD asincrona. Riunione annual Gruppo Italiano Mammella (GIM). Malattia operabile: stato dell'arte tumori Luminali
- October 31, 2020 XXII Congresso Nazionale AIOM 2020. CDK4/6i: dall'evoluzione nel mBC alla rivoluzione nell'eBC. L'evoluzione continua nel trattamento del mBC HR+/HER2-

- October 31, 2020 XXII Congresso Nazionale AIOM 2020. Satellite symposium: Palbociclib: il farmaco che ha tracciato un nuovo percorso di cura per le pazienti con mBC HR+/HER2-. Evidenze di efficacia che hanno tracciato un percorso
- October 23, 2020 ESSO 2020 Virtual. “Neoadjuvant chemotherapy in the era of immunotherapy: the future is bright”
- September 24, 2020 Webinar ReLive ESMO 2020
- September 24, 2020 W4O virtual mentorship session “Optimal time management in paper and grant writing”
- September 7-8, 2020 digital event Young to Young 2020 L’oncologia di domani
- June 23, 2020 Webinar Breast Journal Club “update from ESMO”
- June 18, 2020 VCOE – novità nella Gestione della paziente con carcinoma mammario”
- June 3, 2020 Webinar “Caring for cancer patients during the COVID-19 pandemic; experiences and learnings from a red zone”
- May 24, 2020 ESMO Breast Cancer Virtual Meeting: “Managing side effects of immunotherapy”
- April 22, 2020 Webinar on “Management of cancer patients in COVID era”
- February 13, 2020 San Antonio & Beyond, Rimini – Italy:”Immune checkpoint inhibitors in breast cancer”
- January 10-11, 2020 Back From San Antonio. Genova – Italy: “New biologic findings in HER2+ breast cancer”
- November 29, 2019 Molecular Pathology in interventional radiology - Monza, Italy: “NGS in breast cancer”
- November 16, 2019 Breast Cancer Retreat - Naples, Italy: The role of CDK 4/6 inhibitors in clinical practice
- October 26, 2019 AIOM annual meeting – Rome, Italy: oral presentation “Tumor Infiltrating Lymphocytes (TILs) in ER+/HER2- breast cancer”
- October 18, 2019 W4O post-ESMO meeting – Naples, Italy: Breast cancer updates
- October 11, 2019 SAMO Interdisciplinary Workshop on Breast Tumors- Lucerne, Switzerland: Recent Developments in Metastatic Breast Cancer (Immunotherapy)
- October 4-5, 2019 AIOM Breast cancer, Rome – Italy: Treatment of metastatic HER2-positive breast cancer
- September 28, 2019 ESMO annual meeting, Barcelona – Spain: poster discussion, breast cancer early stage
- September 28, 2019 ESMO annual meeting, Barcelona – Spain: YO boxing session: De-escalation in early HER2+ breast cancer
- September 20, 2019 the breast unit in Oncology, Bergamo Italy: metastatic triple negative breast cancer
- September 12-13 2019 Going beyond in oncology Naples, Italy
- June 14-15 2019 AIOM REVIEW: FROM CHICAGO TO VERONA Verona, Italy: Breast Cancer Poster Review
- May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: “Systemic treatment and metastatic disease: Luminal breast cancer”

- May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: “Systemic treatment and metastatic disease: HER2+ breast cancer”
- May 4, 2019 ESMO Breast Cancer, Berlin – Germany: oral presenter “TILs in ER+/HER2- breast cancer”
- May 4, 2019 ESMO Breast Cancer, Berlin – Germany: invited speaker “Immune therapy as a generalistic approach”
- May 3, 2019 ESMO Breast Cancer, Berlin – Germany: ESMO WEBINAR Enhancing Immunogenicity in “Immune Excluded” or “Immune Desert” Breast Cancers
- May 3, 2019 ESMO Breast Cancer, Berlin – Germany: session coordinator “Vesalius Talk: developing effective leadership skills”
- March 19-20, 2019 DIVE Into Breast Care, Milano-Italy:” CDK4/6 inhibitors in postmenopausal women with metastatic breast cancer”
- February 21-22, 2019 FOCUS SUL CARCINOMA MAMMARIO. Udine –Italy: ”Top-five from ASCO/ESMO”
- January 11-12, 2019 Back From San Antonio. Genova – Italy: “New biologic findings in HER2+ breast cancer”
- November 28, 2018 1st European Course for MSd in training GOING BEYOND IN ONCOLOGY. Milano –Italy:” Integration of new drugs and old drugs into your clinical practice”
- November 9, 2018 17th Stage in Medical Oncology. Taormina – Italy: “Breaking news in ER+ breast cancer”
- October 27, 2018 Innovators in Breast Cancer. Baveno-Italy: “Round Table: The future of Breast Cancer Research: Young Oncologists Corner”
- October 26, 2018 Carcinoma mammario i traguardi raggiunti e le nuove sfide. Roma-Italy: “Terapia sistemica adiuvante: quando e quale?”
- October 13, 2018 Novità in carcinoma mammario, Bari-Italy: “Pazienti “triple positive”: solo ormonoterapia e anti HER-2?”
- June 26, 2018 IL PERCORSO CLINICO-ASSISTENZIALE PER LE DONNE CON TUMORE DELLA MAMMELLA - IX Edizione, Bologna-Italy: “La chemioterapia nel carcinoma mammario metastatico dopo antracicline e taxani in adiuvante: strategia nel 2018
- June 16, 2018 ESMO Leaders Generation Programme. Round Table Discussion in the session on W4O: Women in Oncology. Lugano- Switzerland
- June 16, 2018 invited talk at AIOM post ASCO, Milano- Italy: “ASCO Poster Review”
- May 5-6, 2018 invited talk at Etna Late Spring Meeting 2018 Downsizing surgical treatment with systemic therapies. Giarre (Catania) – Italy: “primary systemic treatment: the very first therapeutic tool? Results from trials”.
- April 14-15, 2018 poster discussant at Okayama TR meeting. Okayama, Japan
- March 24, 2018 chair at CANOA Project. “Breast Cancre: which news in 2018? How to interpret a clinical trial”. Ospedaletto di Pescantina (VR) Italy

- March 8, 2018 invited talk at Women for Women – , Rome Italy: “unmet need in metastatic breast cancer”
- February 10, 2018 invited talk at BREASTorming – dalle evidenze alla pratica clinica nel BC HER2+, Napoli Italy: “Cosa dicono e non dicono le linee guida nel mBC HER2+”
- February 8, 2018 invited talk at PALMARES – Palbociclib il primato dell’innovazione nel mBC, Roma Italy: “Palbociclib in HER2+ disease”
- January 12, 2018 award and invited talk at "Back from San Antonio", Genova Italy: “A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer”
- December 14, 2017 invited speaker at the MBN 2017 Oncoplastic Breast Meeting, Milano Italy: “Primary systemic therapies”
- September 10, 2017 invited speaker at the 2017 ESMO annual meeting, Madrid Spain: ESMO Clinical Practice Guidelines –“Patient with metastatic breast cancer: Sequence of therapies, case presentation”
- September 9, 2017 oral presentation at the 2017 ESMO annual meeting, Madrid Spain: “A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy”
- June 23, 2017 invited speaker at the 2017 Umberto Veronesi MBCC, Milano Italy: “Targeting DNA repair”
- June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: “Breast cancer: Outline of management”
- June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: “Abnormal CXR in a young female”
- May 26, 2017 invited speaker at the “IL TRATTAMENTO DELLA PAZIENTE ANZIANA CON CARCINOMA MAMMARIO” Milano, Italy: therapeutic algorithm in elderly patients with Her2+ mBC
- May 12th, 2017 invited speaker at 8th “Il Percorso Clinico-assistenziale per le donne con tumore della mammella” Bologna, Italy: Immunotherapy
- March 21-23, 2017 invited speaker at 28th International Congress on Anti-Cancer Treatment (ICACT 2017) Paris, France: Genomic predictors of sensitivity to anti-PD1
- March 15, 2017 St Gallen breast cancer conference in Vienna, Austria: Satellite symposium e cancer The coming of age for CDK 4/6 inhibitors, invited speaker on Clinical trial results: the benefits, side effects and costs.
- November 16-17, 2016. Madrid, Spain: Everyday is precious MBC summit
- October 17, 2016 invited speaker at EONS Dublin, Ireland: CDK 4/6 inhibitors: clinical data on breast trials.
- July 7-9, 2016 panelist at Harvard CME course Breast Cancer: New Horizons, Current Controversies, Boston USA.

- June 16-18, 2016 invited speaker at ESSO advanced course on oncoplastic breast surgery. Budapest, Hungary.
- April 2016, invited speaker at “Giornate Salentine in Oncologia” Regional Meeting, Lecce Italy: from gene expression profiling to immunity and microenvironment in breast cancer
- March 2016, invited speaker for European Society of Surgical Oncology Workshop at 10th European Breast Cancer Conference (EBCC-10), Amsterdam, The Netherlands: Value of Tumor-Infiltrating Lymphocytes in Neoadjuvant Treatment: Involvement in Prognosis and Pathologic Complete Response (pCR)
- December 2015, invited speaker at Immuno-Oncology Regional Meeting, Salerno Italy: The role of immunotherapy in the Breast Cancer and Focus on TILs in the Breast Cancer
- November 2015, invited speaker at HER2 + Breast Cancer: Challenges and Unanswered questions. BREAST CANCER PRECEPTORSHIP PROGRAMME. Medical Oncology Department. Ramon y Cajal University Hospital, Madrid, Spain
- October 2014, invited speaker at ESSO, Liverpool UK: Debate: Which is Superior Neoadjuvant Therapy: Endocrine or Systemic Chemotherapy? Pro neoadjuvant chemotherapy
- September 2014, invited speaker at ESMO, Madrid Spain: Contribution of immune response to anti-tumour effect of chemotherapy.
- June 2014 invited speaker at MBCC, Milan Italy: Immunomarkers in early triple negative breast cancer.
- June 2014 invited seminar at MDACC, Houston Texas: the role of tumor infiltrating lymphocytes in breast cancer.
- May 2014 selected abstract for oral presentation at IMPAKT. Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer (BC)
- March 2014 Invited talk: Presentation of a Flims’ protocol. Flims Alumni Club Session – Research Advances and Current Practice in the Management of Breast Cancer. EBCC9, Glasgow Scotland.
- January 2014 Invited talk: “METASTASES: faut-il les biopsier?”. Biennale Monégasque de Cancérologie, Cours Francophone d’Oncologie. Monaco
- June 2013 Invited talk: “Chemotherapy benefit in Luminal breast cancer”. Breast Cancer Progress and Controversies. Naples, Italy.
- “The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery (BCS) following neoadjuvant therapy: analysis from the NeoALTTO trial (BIG 1-06)”: abstract accepted for Proffered Paper (Oral) presentation during the ESMO 2012 Congress, 28 September - 2 October, Vienna, Austria.
- 19-02-2011 Abstract accepted for oral presentation during BSMO (Belgian Society of Medical Oncology), Brussels, Belgium “More advanced stage Luminal A early breast cancers show distinct gene expression patterns associated with worse clinical outcome.
- April 2010 Invited talk: “Biologics in adjuvant setting: where are we?” in: Winter Academy of Oncology: Early breast cancer, Pontresina, Switzerland.

COURSES:

- 2016 ESMO Leaders Generation Programme - Lugano – 27-29 June and 10-12 September 2016
- Breast Cancer Academy – Module 1. Barcelone, Spain 14-15 May 2015. Module 2. Brussels, Belgium 3-4 September 2015. Module 3. Paris, France 19-20 May 2016.
- ECCO-AACR-EORTC-ESMO Workshop "Methods in clinical cancer research". Flims, Switzerland — 18 - 24 June 2011
- Pre-IMPAKT Training Course. Brussels, Belgium 4-5 May 2011.
- EORTC Course “Methodology of cancer clinical trials: the next generation”. Brussels, Belgium 7-10 September 2010.
- Pre-IMPAKT Training Course. Brussels, Belgium 5-6 May 2010.
- The Vito Distante Project in Breast Cancer Clinical Research. Tuscany, Italy 30 August- 2 September 2009
- Pre-IMPAKT Training Course. Brussels, Belgium 6-7 May 2009.

LIST OF PUBLICATIONS:

1. Ascione L, Zagami P, Nicolò E, Crimini E, Curigliano G, **Criscitiello C**. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. *J Pers Med*. 2022 Oct 31;12(11):1793. doi: 10.3390/jpm12111793. PMID: 36579519
2. Corti C, Cobanaj M, Dee EC, **Criscitiello C**, Tolaney SM, Celi LA, Curigliano G. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. *Cancer Treat Rev*. 2023 Jan;112:102498. doi: 10.1016/j.ctrv.2022.102498. Epub 2022 Dec 11. PMID: 36527795
3. Miglietta F, Cinquini M, Dieci MV, Cortesi L, **Criscitiello C**, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Delle Piane C, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. *Breast*. 2022 Oct 29;66:293-304. doi: 10.1016/j.breast.2022.10.014. Online ahead of print. PMID: 36379199
4. **Criscitiello C**, Corti C. Breast Cancer Genetics: Diagnostics and Treatment. *Genes (Basel)*. 2022 Sep 6;13(9):1593. doi: 10.3390/genes13091593. PMID: 36140761
5. Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, **Criscitiello C**, Curigliano G. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? *Eur J Cancer*. 2022 Jun 10;171:25-42. doi: 10.1016/j.ejca.2022.04.039. Online ahead of print. PMID: 35696887
6. Agostinetti E, Montemurro F, Puglisi F, **Criscitiello C**, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. *Cancers (Basel)*. 2022 Apr 25;14(9):2136. doi: 10.3390/cancers14092136. PMID: 35565264
7. Pérez-Fidalgo JA, **Criscitiello C**, Carrasco E, Regan MM, Leo AD, Ribí K, Adam V, Bedard PL. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab +

- chemotherapy in HER2+ PIK3CA-mutated breast cancer. *Future Oncol.* 2022 Apr 25. doi: 10.2217/fon-2022-0045. Online ahead of print. PMID: 35465733
8. Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, **Criscitiello C**, Fusco N. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. *Front Mol Biosci.* 2022 Mar 15;9:834651. doi: 10.3389/fmolb.2022.834651. eCollection 2022. PMID: 35372498
 9. Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, **Criscitiello C**. How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? *ESMO Open.* 2022 Mar 7;7(2):100428. doi: 10.1016/j.esmoop.2022.100428. Online ahead of print. PMID: 35272131
 10. de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, Ammendolia A, **Criscitiello C**, Fusco N, Invernizzi M. Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. *Front Oncol.* 2022 Jan 21;11:829875. doi: 10.3389/fonc.2021.829875. eCollection 2021. PMID: 35127539
 11. Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivinet G, Bellerba F, Trapani D, Marra A, Esposito A, **Criscitiello C**, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. *Eur J Cancer.* 2022 Mar;163:35-43. doi: 10.1016/j.ejca.2021.12.022. Epub 2022 Jan 13. PMID: 35032815
 12. Corti C, Antonarelli G, **Criscitiello C**, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. *Cancer Treat Rev.* 2021 Dec 16;103:102324. doi: 10.1016/j.ctrv.2021.102324. Online ahead of print. PMID: 34953200
 13. Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivinet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, **Criscitiello C**, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. *Cancers (Basel).* 2021 Nov 20;13(22):5829. doi: 10.3390/cancers13225829. PMID: 34830983
 14. Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, **Criscitiello C**. Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. *Histol Histopathol.* 2021 Sep 29;18376. doi: 10.14670/HH-18-376. Online ahead of print. PMID: 34585734
 15. **Criscitiello C**, Marra A, Morganti S, Zagami P, Gandini S, Esposito A, Curigliano G. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. *Eur J Cancer.* 2021 Nov;157:40-49. doi: 10.1016/j.ejca.2021.07.037. Epub 2021 Aug 31. PMID: 34474219
 16. **Criscitiello C**, Spurden D, Piercy J, Rider A, Williams R, Mitra D, Wild R, Corsaro M, Kurosky SK, Law EH. Health-Related Quality of Life Among Patients With HR+/HER2-Early Breast Cancer. *Clin Ther.* 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11. PMID: 34256965
 17. **Criscitiello C**, Guerini-Rocco E, Viale G, Fumagalli C, Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Malapelle U, Fusco N. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. *Anticancer Agents Med Chem.* 2021 Jul 6. doi: 10.2174/1871520621666210706144112. Online ahead of print. PMID: 34229592

18. Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, **Criscitiello C**, Fusco N. Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. *Cells*. 2021 Jun 2;10(6):1377. doi: 10.3390/cells10061377. PMID: 34199522
19. Meattini I, Becherini C, Bernini M, Bonzano E, **Criscitiello C**, De Rose F, De Santis MC, Fontana A, Franco P, Gentilini OD, Livi L, Meduri B, Parisi S, Pasinetti N, Prisco A, Rocco N. Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. *Cancer Treat Rev*. 2021 Sep;99:102236. doi: 10.1016/j.ctrv.2021.102236. Epub 2021 May 27. PMID: 34126314
20. Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, **Criscitiello C**, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. *Expert Opin Biol Ther*. 2021 Jul;21(7):945-962. doi: 10.1080/14712598.2021.1936494. Epub 2021 Jun 15. PMID: 34043927
21. Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, **Criscitiello C**, Tarantino P, Curigliano G. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev*. 2021 Apr 9;97:102205. doi: 10.1016/j.ctrv.2021.102205. Online ahead of print. PMID: 33878560
22. Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, **Criscitiello C**, Vigneri P, Dei Tos AP, Maiorano E, Viale G. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Front Oncol*. 2021 Mar 25;11:644737. doi: 10.3389/fonc.2021.644737. eCollection 2021. PMID: 33842357
23. Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, **Criscitiello C**, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. *ESMO Open*. 2021 Apr 7;6(2):100104. doi: 10.1016/j.esmoop.2021.100104. Online ahead of print. PMID: 33838532
24. Rocco N, Catanuto G, Cinquini M, Audretsch W, Benson J, **Criscitiello C**, Di Micco R, Kovacs T, Kuerer H, Lozza L, Montagna G, Moschetti I, Nafissi N, O'Connell RL, Oliveri S, Pau L, Scaperrotta G, Thoma A, Winters Z, Nava MB. Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. *Breast*. 2021 Feb 26;57:25-35. doi: 10.1016/j.breast.2021.02.013. Online ahead of print. PMID: 33711697
25. Corti C, **Criscitiello C**. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. *ESMO Open*. 2021 Mar 3;6(2):100063. doi: 10.1016/j.esmoop.2021.100063. Online ahead of print. PMID: 33676293
26. Rocco N, Montagna G, **Criscitiello C**, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G. Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. *Genes (Basel)*. 2021 Feb 10;12(2):253. doi: 10.3390/genes12020253. PMID: 33578759
27. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical

- trials. *NPJ Breast Cancer*. 2020 May 12;6(1):15. doi: 10.1038/s41523-020-0155-1. PMID: 33574324
28. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Belloio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6(1):17. doi: 10.1038/s41523-020-0156-0. PMID: 33574291
 29. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2020 May 12;6(1):16. doi: 10.1038/s41523-020-0154-2. PMID: 33574288
 30. **Criscitiello C**, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. *J Hematol Oncol*. 2021 Jan 28;14(1):20. doi: 10.1186/s13045-021-01035-z. PMID: 33509252
 31. Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, **Criscitiello C**, Curigliano G. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. *Eur J Cancer*. 2021 Jan 22;145:197-209. doi: 10.1016/j.ejca.2020.12.028. PMID: 33493979
 32. Tarantino P, Gandini S, Trapani D, **Criscitiello C**, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2021 Jan 19:103223. doi: 10.1016/j.critrevonc.2021.103223. PMID: 33482345.
 33. Invernizzi M, de Sire A, Lippi L, Venetis K, Sajjadi E, Gimigliano F, Gennari A, **Criscitiello C**, Cisari C, Fusco N. Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot

- Study. *Front Oncol.* 2020 Oct 21;10:556718. doi: 10.3389/fonc.2020.556718. eCollection 2020.
34. Marra A, Trapani D, Viale G, **Criscitiello C**, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. *NPJ Breast Cancer.* 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. eCollection 2020. PMID: 33088912
 35. Rocco N, Montagna G, di Micco R, Benson J, **Criscitiello C**, Chen L, Di Pace B, Colmenarejo AJE, Harder Y, Karakatsanis A, Maglia A, Mele M, Nafissi N, Ferreira PS, Taher W, Tejerina A, Vinci A, Nava M, Catanuto G. The impact of the COVID-19 pandemic on surgical management of breast cancer: global trends and future perspectives. *Oncologist.* 2020 Oct 12. doi: 10.1002/onco.13560.
 36. Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, **Criscitiello C**, Locatelli M, Belli C, Bellomi M, Curigliano G. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. *Eur J Cancer.* 2020 Sep 23;139:92-98. doi: 10.1016/j.ejca.2020.08.026
 37. Corti C, Crimini E, **Criscitiello C**, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol.* 2020 Aug 26. doi: 10.1097/CCO.0000000000000678. Online ahead of print. PMID: 32852309
 38. **Criscitiello C**, Marra A, Morganti S, Zagami P, Viale G, Esposito A, Curigliano G. Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials. *Oncologist.* 2020 Aug 12. doi: 10.1634/theoncologist.2020-0518. Online ahead of print. PMID: 32785940
 39. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol.* 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693
 40. **Criscitiello C**, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. *Breast Cancer Res Treat.* 2020 Sep;183(2):347-354. doi: 10.1007/s10549-020-05771-7. Epub 2020 Jul 3. PMID: 32621251
 41. Fusco N, Sajjadi E, Venetis K, Gaudio G, Lopez G, Corti C, Rocco EG, **Criscitiello C**, Malapelle U, Invernizzi M. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? *Genes (Basel).* 2020 Jun 28;11(7):719. doi: 10.3390/genes11070719. PMID: 32605290
 42. Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, **Criscitiello C**, Esposito A, Curigliano G. Pharmacological management of male breast cancer. *Expert Opin Pharmacother.* 2020 Jun 4:1-12. doi: 10.1080/14656566.2020.1763305.
 43. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, **Criscitiello C**, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open.* 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793.
 44. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings

- HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. eCollection 2020.
45. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020.
 46. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2020 May 12;6:16. doi: 10.1038/s41523-020-0154-2. eCollection 2020.
 47. Diana A, Carlino F, Franzese E, Oikonomidou O, **Criscitiello C**, De Vita F, Ciardiello F, Orditura M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. *Cancers (Basel)*. 2020 Mar 29;12(4):819. doi: 10.3390/cancers12040819.
 48. Lambertini M, Toss A, Passaro A, **Criscitiello C**, Cremolini C, Cardone C, Loupakis F, Viscardi G, Meattini I, Dieci MV, Ferrara R, Giusti R, Maio MD. *ESMO Open*. 2020 Mar;5(2). pii: e000759. doi: 10.1136/esmooopen-2020-000759. PMID: 32229501
 49. **Criscitiello C**, Curigliano G. Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. *Eur J Cancer*. 2020
 50. Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, **Criscitiello C**, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast*. 2019

51. Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, **Criscitiello C**, Lovati G, Meliksetyan M, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfrancone L. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res.* 2019
52. **Criscitiello C**, Viale G, Curigliano G. Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. *Curr Opin Oncol.* 2019
53. Park JH, Jonas SF, Bataillon G, **Criscitiello C**, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol.* 2019
54. Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, **Criscitiello C**, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers (Basel).* 2019 Aug 8;11(8).
55. Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, **Criscitiello C**, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer.* 2019
56. **Criscitiello C**, Curigliano G. Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? *Eur J Cancer.* 2019
57. Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, **Criscitiello C**, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. *Cells.* 2019
58. **Criscitiello C**, Viale G, Curigliano G. Peptide vaccines in early breast cancer. *Breast.* 2019
59. Esposito A, Viale G, **Criscitiello C**, Curigliano G. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. *Expert Rev Clin Pharmacol.* 2018
60. Preusser M, De Mattos-Arruda L, Thill M, **Criscitiello C**, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. *ESMO Open.* 2018 Aug 20
61. Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, **Criscitiello C**, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. *Ann Oncol.* 2018 Jun 11.
62. **Criscitiello C**, Santangelo M, Loupakis F. Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. *Biomed Res Int.* 2018 Mar 20
63. **Criscitiello C**, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. *Eur J Cancer.* 2018 Jul

64. Prager GW, Braga S, Bystricky B, Qvortrup C, **Criscitiello C**, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. *ESMO Open*. 2018 Feb 2
65. Arruda LM, **Criscitiello C**, Lambertini M, Argiles G. ESMO Leaders Generation Programme: an alumni insight. *ESMO Open*. 2018 Jan 29
66. **Criscitiello C**, Viale G, Curigliano G, Goldhirsch A. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. *Breast Cancer (Dove Med Press)*. 2018 Jan 30
67. Duso BA, Trapani D, Viale G, **Criscitiello C**, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother*. 2018 Feb;19
68. Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, **Criscitiello C**, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. *Eur J Cancer*. 2017 Dec 8.
69. **Criscitiello C**, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensch N, Curigliano G. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. *Eur J Cancer*. 2017 Nov 15
70. Perri F, Buono G, Schettini F, Arpino G, Bianco R, **Criscitiello C**, De Placido S, Giuliano M. The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? *Anticancer Agents Med Chem*. 2017 Nov 2
71. **Criscitiello C**, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. *Ann Oncol*. 2017 Oct 25
72. **Criscitiello C**, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. *Curr Opin Oncol*. 2017 Nov;29
73. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers

Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Adv Anat Pathol. 2017 Aug 2

74. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep;24
75. Solinas C, Carbognin L, De Silva P, **Criscitiello C**, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast. 2017 Jul 20
76. Trapani D, Esposito A, **Criscitiello C**, Mazzeola L, Locatelli M, Minchella I, Minucci S, Curigliano G. Entinostat for the treatment of breast cancer. Expert Opin Investig Drugs. 2017 Aug;26
77. Curigliano G, **Criscitiello C**. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. J Clin Oncol. 2017 Aug 10.
78. Curigliano G, **Criscitiello C**, Esposito A, Intra M, Minucci S. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opin Drug Metab Toxicol. 2017 Apr 11.
79. Esposito A, **Criscitiello C**, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Curr Oncol Rep. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. Review.
80. Curigliano G, **Criscitiello C**, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. Breast. 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011.
81. Santangelo ML, Grifasi C, **Criscitiello C**, Giuliano M, Calogero A, Dodaro C, Incollingo P, Rupealta N, Candida M, Chiacchio G, Riccio E, Pisani A, Tammaro V, Carlomagno N. Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. Aging Clin Exp Res. 2016 Nov 11. [Epub ahead of print] Review. PMID: 27837464

82. **Criscitiello C**, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol*. 2016 Oct 29. pii: S0748-7983(16)30949-0. doi: 10.1016/j.ejso.2016.10.011. [Epub ahead of print] Review. PMID: 27825710
83. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, **Criscitiello C**, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12646. [Epub ahead of print] PMID: 27779108
84. **Criscitiello C**, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. [Epub ahead of print] Review. PMID: 27744144
85. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw LY, **Criscitiello C**, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart MJ, Michiels S, Lackner MR, Sotiriou C, Loi S. *Ann Oncol*. 2016 Oct;27(10):1860-6. doi: 10.1093/annonc/mdw286. PMID: 27672107
86. Migali C, Milano M, Trapani D, **Criscitiello C**, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol*. 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Review. PMID: 27583028
87. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. PMID: 27557300
88. Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, **Criscitiello C**, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancelli G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat*. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. PubMed PMID: 27372069.
89. **Criscitiello C**, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res*. 2016 Jul;36(7):3537-40. PubMed PMID: 27354620.
90. **Criscitiello C**, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget*. 2016 Jun 13. doi: 10.18632/oncotarget.9966. [Epub ahead of print] PubMed PMID: 27323400.
91. Curigliano G, Cardinale D, Dent S, **Criscitiello C**, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA*

- Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. Review. PubMed PMID: 26919165.
92. Santangelo M, Esposito A, Tammaro V, Calogero A, **Criscitiello C**, Roberti G, Candida M, Rupealta N, Pisani A, Carlomagno N. What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. *Int J Surg*. 2016 Apr;28 Suppl 1:S172-6. doi: 10.1016/j.ijso.2015.12.046. Epub 2015 Dec 18. Review. PubMed PMID: 26708862.
 93. Esposito A, **Criscitiello C**, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther*. 2016 Jan;157:120-4. doi: 10.1016/j.pharmthera.2015.11.007. Epub 2015 Nov 23. Review. PubMed PMID: 26615782.
 94. Esposito A, **Criscitiello C**, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol*. 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225. Review. PubMed PMID: 26447875.
 95. **Criscitiello C**, Esposito A, De Placido S, Curigliano G. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol*. 2015 Nov;27(6):452-6. doi: 10.1097/CCO.0000000000000224. Review. PubMed PMID: 26397764.
 96. Esposito A, **Criscitiello C**, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G. Mechanisms of anorexia-cachexia syndrome and rationale for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev*. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. Review. PubMed PMID: 26386985.
 97. **Criscitiello C**, Curigliano G. Immunotherapy of Breast Cancer. *Prog Tumor Res*. 2015;42:30-43. doi: 10.1159/000437183. Epub 2015 Sep 4. Review. PubMed PMID: 26377084.
 98. **Criscitiello C**, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol*. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review. PubMed PMID: 26238477.
 99. Santangelo ML, **Criscitiello C**, Renda A, Federico S, Curigliano G, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. *Biomed Res Int*. 2015;2015:183523. doi: 10.1155/2015/183523. Epub 2015 Jun 22. PubMed PMID: 26185750; PubMed Central PMCID: PMC4491567.
 100. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. PubMed PMID: 26109735.
 101. Esposito A, **Criscitiello C**, Curigliano G. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr*. 2015 May;2015(51):51-5. doi: 10.1093/jncimonographs/igv012. PubMed PMID: 26063887.
 102. Esposito A, **Criscitiello C**, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early

- breast cancer. *Ecancermedicalscience*. 2015 Mar 31;9:518. doi: 10.3332/ecancer.2015.518. eCollection 2015. PubMed PMID: 25932042; PubMed Central PMCID: PMC4404037.
103. Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, **Criscitiello C**, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast*. 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. PubMed PMID: 25772326.
 104. Carlomagno N, Schonauer F, Tammaro V, Di Martino A, **Criscitiello C**, Santangelo ML. A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report. *J Med Case Rep*. 2015 Jan 26;9:13. doi: 10.1186/1752-1947-9-13. PubMed PMID: 25619316; PubMed Central PMCID: PMC4407615.
 105. **Criscitiello C**, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev*. 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. Review. PubMed PMID: 25499997.
 106. **Criscitiello C**, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol*. 2014 Nov;26(6):551-5. doi: 10.1097/CCO.000000000000122. Review. PubMed PMID: 25279962.
 107. Lammers P, **Criscitiello C**, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel)*. 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. PubMed PMID: 25232798; PubMed Central PMCID: PMC4190498.
 108. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, **Criscitiello C**, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol*. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11. PubMed PMID: 25214542.
 109. **Criscitiello C**, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. Review. PubMed PMID: 25107301.
 110. Esposito A, **Criscitiello C**, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol*. 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. Review. PubMed PMID: 25080998.
 111. **Criscitiello C**, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res*. 2014;16(2):205. Review. PubMed PMID: 25032257; PubMed Central PMCID: PMC4052940.
 112. Locatelli M, **Criscitiello C**, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G. QTc prolongation induced by targeted biotherapies used in clinical practice and

- under investigation: a comprehensive review. *Target Oncol.* 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27. Review. PubMed PMID: 24970120.
113. Ades F, Zardavas D, Pinto AC, **Criscitiello C**, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. *Breast.* 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Review. PubMed PMID: 24794210.
114. Gelao L, **Criscitiello C**, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy.* 2014;6(3):349-60. doi: 10.2217/imt.13.169. Review. PubMed PMID: 24762078.
115. Curigliano G, **Criscitiello C**. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res.* 2014;41:15-35. doi: 10.1159/000355896. Epub 2014 Feb 17. Review. PubMed PMID: 24727984.
116. **Criscitiello C**, Azim HA, de Azambuja E, Rubio IT. Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol.* 2014 Apr;25(4):910-1. doi: 10.1093/annonc/mdu034. PubMed PMID: 24667722.
117. **Criscitiello C**, Gelao L, Viale G, Esposito A, Curigliano G. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig Drugs.* 2014 May;23(5):599-610. doi: 10.1517/13543784.2014.895323. Epub 2014 Mar 5. Review. PubMed PMID: 24597540.
118. Gelao L, **Criscitiello C**, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel).* 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. Review. PubMed PMID: 24594636; PubMed Central PMCID: PMC3968368.
119. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delalogue S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol.* 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol.* 2015 Jul;26(7):1518. PubMed PMID: 24401929; PubMed Central PMCID: PMC3933248.
120. **Criscitiello C**, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Res.* 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. Review. PubMed PMID: 25774617; PubMed Central PMCID: PMC3978442.
121. **Criscitiello C**, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast.* 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. PubMed PMID: 24314620.
122. Esposito A, Bardelli A, **Criscitiello C**, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treat Rev.* 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23. Review. PubMed PMID: 24184333.

123. **Criscitiello C**, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, Curigliano G. No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. *Cancer Epidemiol Biomarkers Prev.* 2014 Jan;23(1):215-7. doi: 10.1158/1055-9965.EPI-13-1041. Epub 2013 Oct 28. PubMed PMID: 24165579.
124. **Criscitiello C**, Curigliano G. Immunotherapeutics for breast cancer. *Curr Opin Oncol.* 2013 Nov;25(6):602-8. doi: 10.1097/CCO.000000000000020. Review. PubMed PMID: 24076578.
125. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast.* 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review. PubMed PMID: 24074802.
126. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Best management of locally advanced inoperable breast cancer. *EJC Suppl.* 2013 Sep;11(2):289-90. doi: 10.1016/j.ejcsup.2013.07.052. Review. PubMed PMID: 26217148; PubMed Central PMCID: PMC4041552.
127. **Criscitiello C**. Tumor-associated antigens in breast cancer. *Breast Care (Basel).* 2012 Aug;7(4):262-6. doi: 10.1159/000342164. PubMed PMID: 23904827; PubMed Central PMCID: PMC3515784.
128. Curigliano G, **Criscitiello C**, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res.* 2013 Oct 15;19(20):5564-71. doi: 10.1158/1078-0432.CCR-12-3697. Epub 2013 Jul 29. Review. PubMed PMID: 23897901.
129. Gelao L, **Criscitiello C**, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G. Tumour dormancy and clinical implications in breast cancer. *Ecancermedicalscience.* 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. Print 2013. PubMed PMID: 23717341; PubMed Central PMCID: PMC3660156.
130. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, **Criscitiello C**, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast.* 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. PubMed PMID: 23642529.
131. Curigliano G, **Criscitiello C**, Andrè F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedicalscience.* 2013 Mar 26;7:299. doi: 10.3332/ecancer.2013.299. Print 2013. PubMed PMID: 23589728; PubMed Central PMCID: PMC3622446.
132. **Criscitiello C**, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol.* 2013 Aug;24(8):1980-5. doi: 10.1093/annonc/mdt129. Epub 2013 Apr 7. PubMed PMID: 23567146.
133. **Criscitiello C**, Curigliano G. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol.* 2013 Feb;9(2):179-81. doi: 10.2217/fon.12.193. PubMed PMID: 23414468.

134. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, **Criscitiello C**, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2012 Oct;23 Suppl 7:vii155-66. PubMed PMID: 22997448.
135. **Criscitiello C**, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C. Understanding the biology of triple-negative breast cancer. *Ann Oncol.* 2012 Aug;23 Suppl 6:vi13-8. Review. PubMed PMID: 23012296.
136. **Criscitiello C**, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Targeted therapies in breast cancer: are heart and vessels also being targeted? *Breast Cancer Res.* 2012 Jun 19;14(3):209. Review. PubMed PMID: 22713170; PubMed Central PMCID: PMC3446327.
137. Brollo J, Curigliano G, Disalvatore D, Marrone BF, **Criscitiello C**, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. *Cancer Treat Rev.* 2013 Feb;39(1):44-50. doi: 10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. Review. PubMed PMID: 22541668.
138. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, **Criscitiello C**, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. *J Clin Oncol.* 2012 Jun 1;30(16):1996-2004. doi: 10.1200/JCO.2011.39.5624. Epub 2012 Apr 16. PubMed PMID: 22508827.
139. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, **Criscitiello C**, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clin Cancer Res.* 2012 Mar 1;18(5):1341-51. doi: 10.1158/1078-0432.CCR-11-2599. Epub 2012 Jan 18. PubMed PMID: 22261811.
140. Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, **Criscitiello C**, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs.* 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. Review. PubMed PMID: 22229343.
141. **Criscitiello C**, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. *Onco Targets Ther.* 2010 Dec 17;4:1-11. doi: 10.2147/OTT.S10155. PubMed PMID: 21552410; PubMed Central PMCID: PMC3084302.
142. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, **Criscitiello C**, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C. HER2-positive circulating tumor cells in breast cancer. *PLoS One.* 2011 Jan 10;6(1):e15624. doi: 10.1371/journal.pone.0015624. PubMed PMID: 21264346; PubMed Central PMCID: PMC3018524.
143. **Criscitiello C**, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. *Curr Opin Oncol.* 2010 Nov;22(6):552-8. doi: 10.1097/CCO.0b013e328333de186. Review. PubMed PMID: 20706122.
144. De Laurentiis M, **Criscitiello C**, Montanino A, Falato C, Plaitano M. [Exemestane in the treatment of breast carcinoma: recent findings]. *Tumori.* 2008 Jan-Feb;94(1):suppl 10-21. Italian. PubMed PMID: 18468352.

145. De Laurentiis M, Canello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, **Criscitiello C**, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *J Clin Oncol*. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PubMed PMID: 18165639.